

65552

L-asparaginase/ASRGL1 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H R Mk	Sensitivity: Endogenous	MW (kDa): 41	Source/Isotype: Rabbit	UniProt ID: #Q7L266	Entrez-Gene Id: 80150
Product Usage Information	e	Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		L-asparaginase/ASRGL1 Antibody recognizes endogenous levels of total L-asparaginase/ASRGL1 protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human L-asparaginase/ASRGL1 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		L-asparaginase (ASRGL1) catalyzes the conversion of L-asparagine to L-aspartate. Research studies have shown that intracellular asparagine can suppress apoptosis in a large number of human tumors (1). In addition, acute lymphocytic leukemia cells frequently depend upon serum asparagine for their viability, as they lack asparagine synthetase (ASNS). Deprivation of asparagine by L-asparaginase has therefore been developed as a therapeutic treatment for acute lymphocytic leukemia (2-3). In <i>KRAS</i> mutant non-small cell lung carcinoma (NSCLC) cells, PI3K/Akt signaling was shown to be required for <i>ASNS</i> expression, suggesting combinatorial Akt inhibition and L-asparaginase treatment as a therapeutic strategy for NSCLC (3). Research studies on a breast cancer model have furthermore shown that restriction of asparagine can suppress cancer metastasis (4).				
Background References		1. Zhang, J. et al. (2014) <i>Mol Cell</i> 56, 205-18. 2. Loayza-Puch, F. et al. (2016) <i>Nature</i> 530, 490-4. 3. Gwinn, D.M. et al. (2018) <i>Cancer Cell</i> 33, 91-107.e6. 4. Knott, S.R.V. et al. (2018) <i>Nature</i> 554, 378-81.				
Species Reacti	ivity	Species reactivity is d	etermined by testin	g in at least one approv	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human R: Rat Mk: Monkey				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks more information.	are the property of	their respective owners.	. Visit cellsignal.com	/trademarks for
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for

diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.